Kintara Therapeutics Analyst Ratings
Kintara Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Kintara Therapeutics (KTRA) rating was a upgraded with a price target of $0.00 to $14.00. The current price Kintara Therapeutics (KTRA) is trading at is $4.60, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/14/2023 | 204.35% | Maxim Group | → $14 | Upgrades | Hold → Buy |
| 09/29/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 05/16/2022 | — | Dawson James | Downgrades | Buy → Neutral | |
| 01/20/2022 | -34.78% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 09/30/2021 | 8.7% | Aegis Capital | $7 → $5 | Maintains | Buy |
| 09/28/2021 | 30.43% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 02/03/2021 | 52.17% | Aegis Capital | $6 → $7 | Maintains | Buy |
| 09/14/2020 | 30.43% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變化 | 上一頁/當前額定值 |
|---|---|---|---|---|---|
| 07/14/2023 | 204.35% | 馬克西姆集團 | → 14 美元 | 升級 | 持有 → 買入 |
| 2022 年 9 月 29 日 | — | 馬克西姆集團 | 降級 | 買入 → 持有 | |
| 2022 年 5 月 16 日 | — | 道森詹姆斯 | 降級 | 買入 → 中性 | |
| 01/20/2022 | -34.78% | HC Wainwright & Co. | 6 美元 → 3 美元 | 維護 | 買 |
| 09/30/2021 | 8.7% | 宙斯盾資本 | 7 美元 → 5 美元 | 維護 | 買 |
| 09/28/2021 | 30.43% | HC Wainwright & Co. | → 6 美元 | 開啓覆蓋範圍 | → 購買 |
| 02/03/2021 | 52.17% | 宙斯盾資本 | 6 美元 → 7 美元 | 維護 | 買 |
| 09/14/2020 | 30.43% | 宙斯盾資本 | → 6 美元 | 開啓覆蓋範圍 | → 購買 |
What is the target price for Kintara Therapeutics (KTRA)?
Kintara Therapeutics（KTRA）的目標價格是多少？
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on July 14, 2023. The analyst firm set a price target for $14.00 expecting KTRA to rise to within 12 months (a possible 204.35% upside). 2 analyst firms have reported ratings in the last year.
Maxim集團於2023年7月14日公佈了Kintara Therapeutics（納斯達克股票代碼：KTRA）的最新目標股價。這家分析公司將目標股價定爲14.00美元，預計KTRA將在12個月內升至12個月內（可能上漲204.35％）。去年有2家分析公司公佈了評級。
What is the most recent analyst rating for Kintara Therapeutics (KTRA)?
分析師對Kintara Therapeutics（KTRA）的最新評級是多少？
The latest analyst rating for Kintara Therapeutics (NASDAQ: KTRA) was provided by Maxim Group, and Kintara Therapeutics upgraded their buy rating.
Kintara Therapeutics（納斯達克股票代碼：KTRA）的最新分析師評級由Maxim集團提供，Kintara Therapeutics上調了買入評級。
When is the next analyst rating going to be posted or updated for Kintara Therapeutics (KTRA)?
Kintara Therapeutics（KTRA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kintara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kintara Therapeutics was filed on July 14, 2023 so you should expect the next rating to be made available sometime around July 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Kintara Therapeutics的高管和客戶交談，以及聽取財報電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Kintara Therapeutics的最後一次評級是在2023年7月14日提交的，因此你應該預計下一個評級將在2024年7月14日左右公佈。
Is the Analyst Rating Kintara Therapeutics (KTRA) correct?
分析師對Kintara Therapeutics（KTRA）的評級正確嗎？
While ratings are subjective and will change, the latest Kintara Therapeutics (KTRA) rating was a upgraded with a price target of $0.00 to $14.00. The current price Kintara Therapeutics (KTRA) is trading at is $4.60, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Kintara Therapeutics（KTRA）評級已上調，目標股價爲0.00美元至14.00美元。Kintara Therapeutics（KTRA）目前的交易價格爲4.60美元，在分析師的預測區間內。
